Worldwide Clinical Trials has partnered with Trialbee to bolster patient enrolment and streamline timelines for clinical trials across the world.
The partnership will integrate worldwide trial infrastructure, therapeutic and recruitment capabilities with technology, real-world data, and nurse call centre qualification.
Worldwide Clinical Trials and Trialbee aim to help trial sponsors better match and recruit eligible participants globally.
Trialbee CEO Matt Walz said: “By combining the global development expertise of Worldwide Clinical Trials with our global patient matching and enrolment platforms, this partnership will lower costs and speed clinical trial timelines with innovative patient matching and enrolment capabilities.”
Identification and retaining of eligible participants are impacted by complex study designs and the need for bigger and diverse patient populations.
More than 50% of regulated trials of small and midsized pharma and biotech companies do not meet their patient recruitment targets, in turn affecting the quality of results and development timelines.
Trial cycle times are also becoming longer due to lowering enrolment and retention associated with changing trends in protocol designs, the companies added.
In Phase II and III trials across all therapeutic areas, 57% and 36% of subjects, respectively, fail to meet screening and randomisation criteria.
Through this collaboration, Worldwide Clinical Trials and Trialbee intend to modify services to cut the drug development cost by matching, enrolling and engaging eligible trial participants across diverse populations globally.
Clients of Worldwide Clinical Trials can now access Trialbee’s data science to improve protocol design and site selection, along with patient identification, recruitment and engagement.
Trialbee Hive provides worldwide access to real-world data and data science to match the most suitable participants and ensure the right population representation.
In August last year, Trialbee partnered with medical data informatics company Clinerion to lower timelines of patient recruitment and enrolment.
In a separate development, Curebase has raised $15m in a Series A funding round to support the development of its decentralised trial software platform and virtual research site capabilities.
The Curebase platform allows patients to participate at home as well as in real-world settings.